BioXcel Therapeutics Inc. (NASDAQ:BTAI) currently has a daily average trading volume of 560.25K but it saw 3131742 shares traded on Thursday. With a market cap of 592.54M USD, stock’s current market price of $19.32 came falling about -25.49 while comparing to the previous closing price of $25.93. In past 52 weeks, the stock remained buoying in the range of price level as high as $34.12 and as low as $8.80. In the recent trading on the day, stock has struck highest price mark of $26.22 while lowest mark touched by it was $17.0001.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Taking a look at 20-day trading activity of BioXcel Therapeutics Inc. (BTAI) gives us an average price of $24.88, while its current price level is -43.38% below from 52-week high level whereas it is 119.67% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $21.47 while that of 200 days or SMA-200 reads an average of $19.80. A closer look into the stock’s movement over the week reveals that its volatility is standing at 15.28% during that period while stretching the period over a month that decreases to 9.50%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 33.37 which implies that the stock is in neutral territory.
BioXcel Therapeutics Inc. (BTAI)’s stock is currently under the radar of 9 analysts who are in consensus at a 12-month price target range of between $24.00 and $75.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $24.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $75.00. Average price target assigned by them is $51.30 which highlights an upside potential of 62.34% for the stock over that period. And to attain the median price target of $47.00 assigned by those analysts, stock has to add about 58.89% of value to its current levels.
Data by FactSet Research shows that 9 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 7 analysts suggested the investors to Buy the stock while 2 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Strong Buy.
Over the week, BTAI’s stock price is moving -27.18% down while it is -7.78% when we observe its performance for the past one month. Year-to-date it is -10.06% down and over the past year, the stock is showing an upside performance of 68.73%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$1.84 beaten by the consensus estimate of -$1.62 for the same. The company is expected to be releasing its next quarterly report in 08/08/2023, for which analysts forecasted an EPS of -$1.71 while estimate for next year EPS is -$6.79. For BTAI, analysts are forecasting an EPS-growth rate of -14.70% for current year and estimate for EPS growth in next year is 24.00%. In next quarter, company is expected to be making quarterly sales of $1.3 million as analysts are expecting the sales for current fiscal year at $4.55 million and seeing the company making $37.39 million in sales next year. Moreover, analysts are in estimates of $510k for current-quarter revenue.
Currently, BioXcel Therapeutics Inc.’s total number of outstanding shares is 28.62M with 31.26% of that held by the insiders while 53.56% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -94.00% and return on equity (ROE) at -177.70%. Stock’s beta reads 1.04. Stock has a price to book (P/B) ratio of 10.44 while price to sale or P/S ratio amounts to 987.57. Its return on asset (ROA) is -85.10% on average.
A filing at the U.S. Securities and Exchange Commission revealed that Fidelity Growth Company Fund came shrinking its share ownership by 1.25% in the BioXcel Therapeutics Inc. (BTAI) increasing its stake to 4.64% with control over 16587.0 shares in the company. As per SEC documents, Fidelity Growth Company Fund sought 1,345,200 of company’s common stock of worth $27.74 million as per recent closing price of the stock. Fidelity Growth Company Fund is not the only institutional holder which restructured its stake in BioXcel Therapeutics Inc., as SPDR S&P Biotech ETF picked 1,283,834 shares of worth $26.47 million to bring its holdings to a total of 22440.0 shares. In the most recent quarter, DNCA Invest – Beyond Global Leade came cutting its stake by -18.18% in the company and now holds 0.9 million or 3.10% of the company’s stake having worth of about 18.56 million.
